MeaseP.J., GenoveseM.C., GreenwaldM.W.. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.N Engl J Med.2014370: 2295–306.
2.
McInnesI.B., SieperJ., BraunJ.. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.Ann Rheum Dis.201473: 349–56.
3.
LebwohlM., StroberB., MenterA.. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.N Engl J Med.2015373: 1318–28.
4.
GriffithsC.E., ReichK., LebwohlM.. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.Lancet.2015386: 541–51.
